Kimialys

Kimialys is a France-based innovator in the biotechnology and life sciences industries, founded in 2020. The company has its roots in a decade of academic research focused on surface chemistry, which is a critical factor in the efficacy of biosensing technologies like rapid tests and real-time sensors. Using their patented K-One® technology, Kimialys enhances diagnostic tests, improving outcomes in sensitivity, specificity, and reproducibility with coated gold nanoparticles.

Beyond diagnostics, the company leverages its expertise in sensor chip functionalization and Surface Plasmon Resonance analysis to better screen and select biologics for both diagnostic and therapeutic applications. By prioritizing precision and reliable biodetection, Kimialys positions itself as a leader in advancing biodetection technologies, emphasizing reliability, robustness, and adaptability.

Notably, the company's growth and innovation received initial support through a Non Equity Assistance investment from AGORANOV on 01 October 2020, enabling them to further develop their groundbreaking solutions.